Share-based Payment Arrangement, Expense of ArriVent BioPharma, Inc. from 31 Mar 2023 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ArriVent BioPharma, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2023 to 31 Dec 2025.
  • ArriVent BioPharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $3,222,000, a 238% increase year-over-year.
  • ArriVent BioPharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $12,520,000, a 290% increase year-over-year.
  • ArriVent BioPharma, Inc. annual Share-based Payment Arrangement, Expense for 2025 was $12,520,000, a 290% increase from 2024.
  • ArriVent BioPharma, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $3,208,000, a 258% increase from 2023.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

ArriVent BioPharma, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $12,520,000 $3,222,000 +$2,270,000 +238% 01 Oct 2025 31 Dec 2025 10-K 05 Mar 2026 2025 FY
Q3 2025 $10,250,000 $3,716,000 +$2,851,000 +330% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $7,399,000 $3,311,000 +$2,545,000 +332% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $4,854,000 $2,271,000 +$1,646,000 +263% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $3,208,000 $952,000 +$409,223,000 01 Oct 2024 31 Dec 2024 10-K 05 Mar 2026 2025 FY
Q3 2024 $406,015,000 $865,000 -$215,135,000 -100% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $190,880,000 $766,000 -$192,234,000 -100% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $1,354,000 $625,000 +$459,000 +277% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $895,000 $408,271,000 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q3 2023 $216,000,000 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $193,000,000 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $166,000 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1

ArriVent BioPharma, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $12,520,000 +$9,312,000 +290% 01 Jan 2025 31 Dec 2025 10-K 05 Mar 2026 2025 FY
2024 $3,208,000 +$2,313,000 +258% 01 Jan 2024 31 Dec 2024 10-K 05 Mar 2026 2025 FY
2023 $895,000 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.